Inalimarev

Description

Inalimarev is an investigational vaccine therapy being studied for colorectal cancer patients who have had surgery to remove liver or lung metastases (cancer that has spread). It is currently in Phase 2 clinical trials. The goal of this vaccine is to stimulate the patient's own immune system to recognize and attack cancer cells that might remain after surgery. It is being tested in combination with other treatments, including Sargramostim (GM-CSF), which helps boost the immune response. The trial compares Inalimarev given with autologous dendritic cells (cells from the patient's own immune system) versus Inalimarev given with Sargramostim. The primary goal is to see if this vaccine therapy improves disease-free survival (the time after treatment when there is no sign of cancer) compared to standard care or other treatments. It is not yet approved for use in colorectal cancer.

Mechanism of Action

Inalimarev is a type of cancer vaccine. It works by introducing specific antigens (proteins) found on colorectal cancer cells, such as CEA (Carcinoembryonic antigen) and MUC-1 (Mucin 1), into the patient's body. These antigens are delivered using viral vectors (vaccinia and fowlpox viruses) and sometimes combined with the patient's own dendritic cells (immune cells that help activate the immune system). The goal is to train the patient's immune system, specifically T-cells, to recognize these cancer-specific antigens and target any remaining cancer cells, preventing the cancer from returning or spreading further. The specific costimulatory molecules (TRICOM) are included to enhance the immune response.

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials